Major decreases in cancer mortality have been driven by improvements in the management of lung cancer. The explanation for these survival improvements is complex but largely driven by the increasing use of systemic therapies in early stage disease such as immunotherapy. Additionally, local ablative therapies in advanced stage disease are also improving outcomes. Translation of these practices into community based setting is important. This educational activity will help participants to better apply new treatment strategies so that patient outcomes can be enhanced. Additionally, it will provide insight into where current deficits in management remain and future studies to answer these questions.
The activity is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, nurses and all other health professionals involved in the field of radiation oncology.
Upon completion of this activity, participants should be able to do the following:
- Describe the increasing use of immunotherapy with non-metastatic lung cancer.
- Apply principles of when radiotherapy is appropriate (and when it is not) in advanced lung cancer.
- Explore the evolving treatment options for locally advanced, resectable lung cancer.
Russell Hales, MD, is employed by Johns Hopkins University and has no financial relationships with a commercial interest.
All relevant relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.50 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.